Radiotherapy and AI in the future of prostate cancer treatment

• Date :
• 9    
  0

PARP inhibitors: activity in BRCA1 versus BRCA2 altered mCRPC

• Date :
• 3    
  0

Characterization of PSA responses to bipolar androgen therapy in mCRPC

• Date :
• 2    
  0

PICK-NEPC: avelumab in NEPC/AVPC

• Date :
• 2    
  0

Disparities in cancer care during COVID-19

• Date :
• 2    
  0

Combinatorial biomarkers predict responses to ICI in mUC

• Date :
• 1    
  0

Targeting PSMA in mCRPC

• Date :
• 1    
  0

KEYNOTE-992: pembrolizumab plus chemoRT for MIBC

• Date :
• 1    
  0

ARCHES: enzalutamide plus ADT in mHSPC subgroups

• Date :
• 1    
  0

Biomarkers for novel RCC and urothelial carcinoma treatments

• Date :
• 1    
  0

Favorable traits in metastatic RCC

• Date :
• 1    
  0

SPORT: P-SABR versus PPN-SABR for localized prostate cancer

• Date :
• 1    
  0

5-ARIs: impacts on prostate volume and PSA

• Date :
• 1    
  0

BTCRC-GU15-023: DUART plus adjuvant durvalumab in bladder cancer

• Date :
• 1    
  0

Comparing ICI outcomes in upper and lower tract urothelial carcinoma

• Date :
• 1    
  0

Radioligands in the future of prostate cancer treatment

• Date :
• 1    
  0

Genomic and clinical features of SPOP mutations in prostate cancer

• Date :
• 1    
  0

Real-world practice & outcomes in mCSPC

• Date :
• 0    
  0

STRONG: fixed-dose durvalumab for UTC

• Date :
• 0    
  0

Advanced & metastatic prostate cancer at ASCO GU

• Date :
• 0    
  0

Predicting long-term benefit from ICIs in mUC

• Date :
• 0    
  0

Exciting ongoing trials in urothelial cancer

• Date :
• 0    
  0

VEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancer

• Date :
• 0    
  0

Kidney cancer at ASCO GU: PAPMET & CLEAR

• Date :
• 0    
  0

WST11 vascular-targeted photodynamic therapy in UTUC

• Date :
• 0    
  0

Checkmate 274 & EV-301: highlights in UC from ASCO GU

• Date :
• 0    
  0

TROPiCS-04: sacituzumab govetican in mUC

• Date :
• 0    
  0

PD1/L1 inhibitors with ACEIs and ARBs improves tumor regression for mUC

• Date :
• 0    
  0

INTACT: safety results of CRT with and without atezolizumab in MIBC

• Date :
• 0    
  0

nmCRPC at ASCO GU: ARAMIS & PROSPER

• Date :
• 0    
  0

CTC enumeration as a prognostic biomarker in prostate cancer

• Date :
• 0    
  0

TheraP: cabazitaxel versus 177Lu-PSMA-617 for mCRPC

• Date :
• 0    
  0

PAPMET: MET inhibitors in treating papillary renal cell carcinoma

• Date :
• 0    
  0

Assessing the impact of ADT in patients with prostate cancer and COVID-19

• Date :
• 0    
  0

Using the polygenic risk score for targeted prostate cancer screening

• Date :
• 0    
  0

Angiogenic and T-effector subgroups and propensity for PBRM1 and BAP1 alterations in ccRCC

• Date :
• 0    
  0

OS of patients with mCRPC with PTEN loss-of-function identified by genomic profiling

• Date :
• 0    
  0

The impact of antibiotic use on ICI treatment in mUC

• Date :
• 0    
  0

Highlights in urothelial cancer for ASCO GU 2021

• Date :
• 0    
  0

Highlights in bladder cancer from ASCO GU 2021

• Date :
• 0    
  0

SEMS: surgery as first-line therapy for seminoma

• Date :
• 0    
  0

CA 125, CA19-9 and CEA: tumor markers in bladder cancer

• Date :
• 0    
  0

Current treatment landscape of seminoma

• Date :
• 0    
  0

The history of biomarkers in the treatment of prostate cancer

• Date :
• 0    
  0

Prognostic biomarkers to guide treatment of mCRPC

• Date :
• 0    
  0

State of the art research in bladder cancer treatment

• Date :
• 0    
  0

18F-fluciclovine PET in mCRPC treated with abiraterone acetate

• Date :
• 0    
  0

Key updates in bladder cancer from ASCO GU 2021

• Date :
• 0    
  0

177Lu-PSMA-617 for prostate cancer: TheraP, VISION, UpFrontPSMA and LuTectomy

• Date :
• 0    
  0

Integration of mental health metrics into patient-centered care

• Date :
• 0    
  0

Impact of telemedicine on patient-reported outcomes in urologic oncology

• Date :
• 0    
  0

The impact of COVID-19 on genitourinary cancer care

• Date :
• 0    
  0

Immunotherapy in the evolving MIBC treatment landscape

• Date :
• 0    
  0

CTC counts using Epic Sciences for mCRPC

• Date :
• 0    
  0

STARTAR: ADT + apalutamide + RT + docetaxel for PSA-recurrent prostate cancer following RP

• Date :
• 0    
  0

5-ARIs impact prostate cancer outcomes due to delayed diagnosis

• Date :
• 0    
  0

INSPIRE: bladder-sparing chemoRT with durvalumab in LN+ urothelial cancer

• Date :
• 0    
  0

BREAKPOINT: cabozantinib after first-line ICI in RCC

• Date :
• 0    
  0

Gemcitabine plus doxorubicin for RMC

• Date :
• 0    
  0

Sitravatinib, nivolumab and ipilimumab for accRCC

• Date :
• 0    
  0

Latest updates in PSMA imaging for prostate cancer

• Date :
• 0    
  0

Opaganib for mCRPC after abiraterone or enzalutamide

• Date :
• 0    
  0

Impact of intact P-Rmass on ICI response in mRCC

• Date :
• 0    
  0

Bevacizumab plus erlotinib for RMC

• Date :
• 0    
  0

Long-term survival outcomes for mRCC after cytoreductive neprectomy

• Date :
• 0    
  0

The adoption of ICI maintenance therapy in mUC in the US

• Date :
• 0    
  0

Vascular-targeted photodynamic therapy

• Date :
• 0    
  0

EV-201, EV-301 and UNITE: enfortumab vedotin in advanced urothelial cancer

• Date :
• 0    
  0

NAXIVA: axitinib for reducing VTT in RCC

• Date :
• 0    
  0

Association between TMB and irAEs during ICI therapy in patients with mUC

• Date :
• 0    
  0

SAPROCAN: saracatinib and docetaxel for mCRPC

• Date :
• 0    
  0

Prognostic impact of bone metastasis in UC

• Date :
• 0    
  0

First-line ICIs in advanced non-clear cell RCC

• Date :
• 0    
  0

Real-world survival in mHSPC following abiraterone or docetaxel therapy

• Date :
• 0    
  0

Extended follow-up data from POUT in urothelial cancer

• Date :
• 0    
  0

RETAIN BLADDER: a risk-adapted approach to muscle invasive bladder cancer

• Date :
• 0    
  0

Apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mCRPC

• Date :
• 0    
  0

Association of response to first-line chemotherapy with atezolizumab efficacy in mUC

• Date :
• 0    
  0

RESORT follow-up: radical metastasectomy plus sorafenib in mRCC

• Date :
• 0    
  0

Immunotherapeutic targets and therapy for RCC

• Date :
• 0    
  0

The emerging role of PARP inhibitors in prostate cancer

• Date :
• 0    
  0

CABEYOND: cabozantinib beyond PD and survival outcomes in mRCC

• Date :
• 0    
  0

44e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse

• Date :
• 4178    
  0

14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024

• Date :
• 3838    
  0

Post ASCO-ESMO 2024 Fédération Francophone de Cancérologie Digestive

• Date :
• 3169    
  0

45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024

• Date :
• 6927    
  0

Molecular Analysis for Precision Oncology Congress - MAP 2024

• Date :
• 2504    
  0